[1] Ioannou GN, Green P, Kerr KF, et al. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol,2019,71:523-533.
[2] Xie DY, Ren ZG, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobil Surg Nutr,2020,9:452-463.
[3] Renner P, Schuhbaum J, Kroemer A, et al. Morbidity of hepatic resection for intermediate and advanced hepatocellular carcinoma. Langenbecks Arch Surg,2015,401:43-53.,
[4] Xie QS, Chen ZX, Zhao YJ, et al. Systematic review of outcomes and meta-analysis of risk factors for prognosis after liver resection for hepatocellular carcinoma without cirrhosis. Asian J Surg,2021,44:36-45.
[5] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版). 中国实用外科杂志,2022,42:241-273.
[6] 海峡两岸医药卫生交流协会肿瘤防治专家委员会. 肝癌肝切除围手术期管理中国专家共识(2021年版). 中华肿瘤杂志,2021,43:414-430.,
[7] 沈英皓, 孙惠川, 周俭. 肝切除术前肝脏储备功能评估. 中华肝脏外科手术学电子杂志 2019,8:469-472.
[8] Berzigotti A, Reig M, Abraldes JG, et al. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. Hepatology,2015,61:526-536.
[9] 董家鸿, 郑树森, 陈孝平,等. 肝切除术前肝脏储备功能评估的专家共识(2011版). 中华消化外科杂志 2011:20-25.
[10] Prodeau M, Drumez E, Duhamel A, et al. An ordinal model to predict the risk of symptomatic liver failure in patients with cirrhosis undergoing hepatectomy. Journal of Hepatology 2019;71:920-929.
[11] Yang Sl, Liu LP, Sun Yf, et al. Distinguished prognosis after hepatectomy of HBV-related hepatocellular carcinoma with or without cirrhosis: a long-term follow-up analysis. J Gastroenterol,2015,51:722-732.
[12] 韩秀国. 有无肝硬化的肝癌患者围手术期并发症及其危险因素的对比研究. 第三军医大学, 2016.
[13] Sangiovanni A, Colombo M. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int,2016,36:124-129.
[14] Golfieri R, Bargellini I, Spreafico C, et al. Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. Liver Cancer,2019,8:78-91.
[15] Dong ZR, Zou J, Sun D, et al. Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis. J Cancer, 2017,8:3862-3867.
[16] Kamath P. A model to predict survival in patients with end-stage liver disease. Hepatology, 2001,33:464-470.
[17] Chen X, Zhai J, Cai X, et al. Severity of portal hypertension and prediction of postoperative liver failure after liver resection in patients with Child–Pugh grade A cirrhosis. Brit J Surg,2012,99:1701-1710.
[18] Roayaie S, Jibara G, Tabrizian P, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology,2015,62:440-451.
[19] 章越, 聂源, 蒋美纯, 等. 慢加急性肝衰竭预后评分应用进展. 天津医药,2020,48:780-785.
[20] Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology,2000,31:864-871.
[21] 尹子霄, 曹源, 单人锋, 等. Child-Pugh、MELD、ALBI评分预测肝癌R_0切除术后肝衰竭风险的比较. 中国普通外科杂志,2017,26:847-854.
[22] D'Amico G, Maruzzelli L, Airoldi A, et al. Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. J Hepatol,2021,75:1355-1366.
[23] Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade. J Clin Oncol,2015,33:550-558.
[24] Pinato DJ, Sharma R, Allara E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol,2017,66:338-346.
[25] Toyoda H, Lai PBS, O'Beirne J, et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Brit J Cancer,2016,114:744-750.
[26] Kariyama K, Nouso K, Hiraoka A, et al. EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. Liver Cancer,2020,9:734-743.
[27] 代俊龙, 李川, 张宇, 等. 基于简化白蛋白-胆红素评分的多中心验证研究:一项预测肝细胞癌切除术后并发症和生存时间的新模型. 中国普外基础与临床杂志,2022.
[28] Haruki K, Shiba H, Saito N, et al. Risk stratification using a novel liver functional reserve score of combination prothrombin time–international normalized ratio to albumin ratio and albumin in patients with hepatocellular carcinoma. Surgery,2018,164:404-410.
[29] Longheval G. Predictive models of short- and long-term survival in patients with nonbiliary cirrhosis. Liver Transpl,2003,9:260-267.
[30] Kong FH, Miao XY, Zou H, et al. End-stage liver disease score and future liver remnant volume predict post-hepatectomy liver failure in hepatocellular carcinoma. World J Clin Cases, 2019,7:3734-3741.
[31] 李相成, 卢倩, 段伟东,等 精准肝切除术专家共识. 中华消化外科杂志,2017,16:883-893.
[32] Imamura H, Sano K, Sugawara Y, et al. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg,2005,12:16-22.
[33] Ibis C, Albayrak D, Sahiner T, et al. Value of Preoperative Indocyanine Green Clearance Test for Predicting Post-Hepatectomy Liver Failure in Noncirrhotic Patients. Med Sci Monit,2017,23:4973-4980.
[34] Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol,2018,69:182-236.
[35] Citterio D, Facciorusso A, Sposito C, et al. Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma. JAMA Surg,2016,151.
[36] 康宁, 齐丽翠, 袁岳, 等. PTAR联合Child-Pugh及MELD评分对肝硬化患者发生慢加急性肝衰竭预测价值研究. 胃肠病学和肝病学杂志,2020,29:1171-1178.
[37] Zou H, Wen Y, Yuan K, et al. Combining albumin-bilirubin score with future liver remnant predicts post-hepatectomy liver failure in HBV-associated HCC patients. Liver Int,2018,38:494-502.
[38] Mai RY, Zeng J, Lu HZ, et al. Combining Aspartate Aminotransferase-to-Platelet Ratio Index with Future Liver Remnant to Assess Preoperative Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma. J Gastrointest Surg,2020,25:688-697. |
